Company / Capital Expenditures
Bristol Myers Squibb Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.3B
FY2025
5-year range
$753.0M / $1.3B
FY2021-FY2025
Trend
+5.0%
vs FY2024
Sector context
#5 of 194
Health Care
What the data says
Among 194 Health Care companies, Bristol Myers Squibb is in the top 3% for capital expenditures. Capital Expenditures has increased for 3 consecutive years, from $753M in FY2022 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +11.7%. Top quartile in the Health Care sector.
Improved from $973M to $1.3B over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +20.3%
- 5-Year CAGR
- +11.7%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 194This company $1.3B Sector average $117.5M
▼
+1015.6% above sector average
Key checks
Key Insights
- Bristol Myers Squibb's capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of +11.7%, indicating consistent growth.
- In FY2025, capital expenditures increased 5.0% year-over-year.
- Ranks #5 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +5.0% |
| FY2024 | $1.2B | +28.3% |
| FY2023 | $973.0M | +29.2% |
| FY2022 | $753.0M | -9.9% |
| FY2021 | $836.0M | +11.0% |
| FY2020 | $753.0M | -28.6% |
| FY2019 | $1.1B | -13.2% |
| FY2018 | $1.2B | +15.2% |
| FY2017 | $1.1B | +100.6% |
| FY2016 | $526.0M | -2.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026